Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – Molecular bilayer structure
Patent
1978-02-22
1980-10-21
Padgett, Benjamin R.
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
Molecular bilayer structure
23230B, 260112R, 424 12, G01N 3316, A61K 3900, A61K 4300
Patent
active
042294266
ABSTRACT:
This disclosure relates to assay of a glycoprotein component of human breast gross cystic disease fluid which has been designated GCDFP-15. This material is a useful marker in monitoring the efficacy of therapy in women with metastatic breast carcinoma and also in determining the maturity of the fetus in pregnant women. The assay for GCDFP-15 can also be used in conjunction with other assays for breast carcinoma such as an assay for carcinoembryonic antigen (CEA) whereby the utilization of both tests is more effective in monitoring for recurrence of disease than using either assay alone.
REFERENCES:
Haagensen et al., Annals of Surgery, vol. 185, No. 3, Mar. 1977, pp. 279-285.
Duke University, Inc.
Gould George M.
Leon Bernard S.
Nucker Christine M.
Padgett Benjamin R.
LandOfFree
Breast cyst fluid protein assay does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Breast cyst fluid protein assay, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Breast cyst fluid protein assay will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2022693